TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
TriSalus Life Sciences names new finance chief [Seeking Alpha]
TriSalus Announces Leadership Changes
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $10.00 price target on the stock.
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $12.00 to $11.00. They now have a "buy" rating on the stock.